# A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

> **NCT03511963** · PHASE3 · COMPLETED · sponsor: **Shanghai Henlius Biotech** · enrollment: 677 (actual)

## Conditions studied

- Metastatic Colorectal Cancer (mCRC)

## Interventions

- **DRUG:** HLX04 100 mg in 4 ml Injection
- **DRUG:** Avastin 100 mg in 4 ml Injection

## Key facts

- **NCT ID:** NCT03511963
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2020-04-15
- **Final completion:** 2023-04-20
- **Target enrollment:** 677 (ACTUAL)
- **Last updated:** 2024-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03511963

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03511963, "A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03511963. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*